Original ResearchPublished 26 August 2026Real-world outcomes of sitagliptin and sitagliptin/metformin single-pill combination treatment in diverse type 2 diabetes populations (DIVERSITY study)Andrej Janez · Mirjana Bojic · Tomislav Bozek · Zdravko Kamenov · Tatjana Milenkovic · Gabriela Radulian · Tamás VárkonyiFrontiers in Clinical Diabetes and Healthcaredoi 10.3389/fcdhc.2026.1905393
CorrectionPublished 6 July 2026Correction: Exploring factors predicting the effectiveness of oral semaglutide in Japanese individuals with type 2 diabetes switching from dipeptidyl peptidase 4 inhibitors: a pilot studyTakao Hirotsu · Kanta Taniguchi · Rimei NishimuraFrontiers in Clinical Diabetes and Healthcaredoi 10.3389/fcdhc.2026.1914250
Original ResearchPublished 10 June 2026Comprehensive pharmacovigilance assessment of pairwise drug–drug interactions and acute pancreatitis in the FDA adverse event reporting system: focus on incretin-based drugsIssei Kazume · Kenji Onda · Sachiko Tanaka · Takashi Yokokawa · Kenichi SuzukiFrontiers in Drug Safety and Regulationdoi 10.3389/fdsfr.2026.1827098
